ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230997
Recruitment Status : Completed
First Posted : October 3, 2005
Last Update Posted : December 16, 2005
Sponsor:
Collaborator:
Ortho-McNeil Neurologics, Inc.
Information provided by:
Neurological Research Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : August 2004
Publications of Results:
Edwards K, Farlow M, Hake A et al. An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients with Dementia with Lewy Bodies. Neurobiology of Aging. 2004; 25 (S2): 21.
Edwards K, Hershey L, Farlow M, Lichter D, Johnson S: Galantamine for the treatment of dementia with Lewy bodies. Movement Disorders: S336, Vol 19/Suppl 9, 2004

Other Publications:
Tonkopii, V.D., Prozorovskii, V.B. and Suslova, I.M. Interaction of reversible inhibition with catalytic centers and allosteric site of cholinesterases. Bull. Exp. Bio. Med., 82:1180-1183, 1976